SLC6A8: A Potential Drug Target and Biomarker for Neurotransmitter Transporter

Target Name: SLC6A8

NCBI ID: G6535

SLC6A8

SLC6A8: A Potential Drug Target and Biomarker for Neurotransmitter Transporter

SLC6A8, a member of the SLC6A family, is a protein that is expressed in various tissues of the brain and plays a critical role in neurotransmitter transporter. It is a transmembrane protein that is composed of an intracellular N-terminus, a catalytic C-terminus, and an extracellular C-terminus. SLC6A8 is involved in the transport of various neurotransmitters, including dopamine, serotonin, and endocannabinoids.

SLC6A8 is a well-established gene that has been studied extensively in the context of neurotransmitter transport. It is highly expressed in the brain and is mainly expressed in the prefrontal cortical regions of the brain. SLC6A8 is also expressed in other tissues, including the liver, heart, and kidney.

SLC6A8 has been identified as a potential drug target due to its involvement in neurotransmitter transport. The neurotransmitters that are transported by SLC6A8 can play a crucial role in the function of the brain and are involved in various neurological disorders, including depression, anxiety, and neurodegenerative diseases.

SLC6A8 has also been identified as a potential biomarker for neurodegenerative diseases. The loss of SLC6A8 has been observed in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The decreased expression of SLC6A8 has been observed in the brains of individuals with these disorders, which suggests that it may be a useful biomarker for the diagnosis and progression of these diseases.

In addition to its potential drug and biomarker applications, SLC6A8 is also involved in the regulation of neurotransmitter transport. SLC6A8 is a member of the T-type Ca2+-ATPase (Ca2+-ATPase) family, which is involved in the regulation of intracellular Ca2+ levels. The Ca2+-ATPase is a critical enzyme that is involved in various physiological processes, including neurotransmitter transport.

SLC6A8 is also involved in the regulation of neurotransmitter transport in the nervous system. SLC6A8 is a component of the neurotransmitter transporter complex, which is responsible for the transport of neurotransmitters across the blood-brain barrier. The neurotransmitter transporter complex is a critical pathway for the delivery of neurotransmitters to the brain and is involved in the regulation of various neurological disorders, including depression and anxiety.

In conclusion, SLC6A8 is a well-established protein that is involved in the transport of neurotransmitters across the blood-brain barrier. Its involvement in neurotransmitter transport and regulation makes it a potential drug target and biomarker for various neurological disorders. Further research is needed to fully understand the role of SLC6A8 in neurotransmission and to develop effective treatments for neurodegenerative diseases.

Protein Name: Solute Carrier Family 6 Member 8

Functions: Creatine:sodium symporter which mediates the uptake of creatine (PubMed:7953292, PubMed:7945388, PubMed:9882430, PubMed:17465020, PubMed:22644605, PubMed:25861866). Plays an important role in supplying creatine to the brain via the blood-brain barrier (By similarity)

The "SLC6A8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets